Arcutis Biotherapeutics, Inc.
NASDAQ:ARQTBiotechnology
-$0.51 today
- Market cap
- $3.49B
- Beta
- 1.52
- P/E (TTM)
- -1400.0
- EPS (TTM)
- -$0.02
Volume 0.84M
Average 1.61M
ARQT Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Arcutis Biotherapeutics, Inc.NASDAQ: ARQT
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development grows, but more slowly than its trailing trend
Q2 FY2026 research & development of $20.36M rose 4.6% year over year, behind the +28.3% change in trailing-twelve-month research & development. Sequentially, it fell 33.5% from the prior quarter. Over 3 fiscal years it compounded at -25.0% a year.
Context
- Research & development amounted to 20.5% of revenue in FY2025, down 18.4 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +4.6% toward the trailing-twelve-month pace of +28.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 77.05M USD
- Year-over-year change
- +0.8%
- 4-year CAGR
- -14.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 77.05M | +0.8% |
| FY2024 | 2024-12-31 | 76.42M | -30.9% |
| FY2023 | 2023-12-31 | 110.58M | -39.4% |
| FY2022 | 2022-12-31 | 182.44M | +25.3% |
| FY2021 | 2021-12-31 | 145.56M | — |
Research & Development vs competitors
How ARQT compares with its peers on the latest reported figures
- ARQT's LTM Jun 2026 research & development of $91.04M is the highest of the 6 companies compared; the peer median is $20.65M.
- Its year-over-year change of +28.3% is the 2nd highest of 4, against a peer median of -21.4%.
- Research & development amounts to 19.6% of revenue for ARQT, versus a peer median of 677.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $91.04M | +28.3% | -25.0% | 19.6% | |
EVMNEvommune, Inc. | LTM Mar 2026 | $77M | — | — | 770.0% |
| LTM Mar 2026 | $56.72M | +60.6% | -12.2% | 677.9% | |
| LTM Mar 2026 | $20.65M | -58.3% | -18.4% | — | |
| LTM Mar 2026 | $16.75M | -21.4% | +21.6% | 90.7% | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | $365.75K | — | — | — |
| Peer median (excluding ARQT) | $20.65M | -21.4% | -12.2% | 677.9% | |
Competitors are the stored peer set for ARQT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 3.69M | 59.61M | 196.54M | 376.07M |
| Cost of Revenue | 763K | 754K | 4.99M | 19.13M | 36.7M |
| Gross Profit | (763K) | 2.93M | 54.62M | 177.41M | 339.38M |
| Gross Margin | — | 79.5% | 91.6% | 90.3% | 90.2% |
| Research & Development | 145.56M | 182.44M | 110.58M | 76.42M | 77.05M |
| Selling, General & Admin | 60.97M | 122.12M | 185.15M | 229.39M | 274.55M |
| Operating Expenses | 205.77M | 304.56M | 295.72M | 305.81M | 351.6M |
| Depreciation & Amortization | 454K | 934K | 750K | 2.6M | 4.67M |
| EBITDA | (205.9M) | (294.87M) | (228.57M) | (109.63M) | 1.78M |
| EBITDA Margin | — | -7999.8% | -383.5% | -55.8% | 0.5% |
| Operating Income | (206.53M) | (301.63M) | (241.1M) | (128.4M) | (12.23M) |
| Operating Margin | — | -8183.0% | -404.5% | -65.3% | -3.3% |
| Interest Income | 173K | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 15.65M | 29.71M | 27.17M | 12.08M |
| Other Income / Expenses | 173K | (9.83M) | (17.93M) | (11M) | (2.74M) |
| Income Before Tax | (206.36M) | (311.46M) | (259.03M) | (139.39M) | (14.97M) |
| Pre-Tax Margin | — | -8449.8% | -434.6% | -70.9% | -4.0% |
| Income Tax Expense | 0 | 0 | 3.11M | 647K | 1.17M |
| Net Income | (206.36M) | (311.46M) | (262.14M) | (140.04M) | (16.14M) |
| Net Margin | — | -8449.8% | -439.8% | -71.3% | -4.3% |
| EPS (Basic) | (4.17) | (5.66) | (3.78) | (1.16) | (0.13) |
| EPS (Diluted) | (4.17) | (5.66) | (3.78) | (1.16) | (0.13) |
| Weighted Avg Shares | 49.41M | 55.03M | 69.31M | 120.96M | 127.23M |
| Weighted Avg Shares (Diluted) | 49.41M | 55.03M | 69.31M | 120.96M | 127.23M |
Arcutis Biotherapeutics, Inc.
NASDAQ:ARQT
Intrinsic Alpha fair value
Locked
Current Price
$27.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.